Developing a set of recommendations for the future of the Food and Drug Administration

The Manhattan Institute for Policy Research released a white paper on June 8, 2006, with recommendations on how to reform the pipeline for new medications, including the approval process by the Food and Drug Administration (FDA).

The white paper, Prescription for Progress: The Critical Path To Drug Development, was written in response to a 2004 FDA report that concluded that the lengthy and costly approval process hinders development of treatments for small populations of patients with certain serious diseases.